TNF and histiocytic sarcoma: Healthy non-lesional skin in HS patients is functionally different from healthy non-lesional skin in healthy subjects regarding their immune responses and regulatory pathways. Anti-TNF-α therapy reduced B cell activation without significantly altering other inflammatory pathways.